...
首页> 外文期刊>Diseases of the Colon and Rectum >Treatment of recurrence after transanal endoscopic microsurgery (TEM) for T1 rectal cancer.
【24h】

Treatment of recurrence after transanal endoscopic microsurgery (TEM) for T1 rectal cancer.

机译:经肛门内镜显微手术(TEM)治疗T1直肠癌后的复发治疗。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: The aim of this study was to evaluate the management and outcome of local recurrences after transanal endoscopic microsurgery for T1 rectal cancer. METHODS: Consecutive patients who underwent transanal endoscopic microsurgery for pT1 rectal cancer at a Dutch referral center (IJsselland Hospital) were registered in a prospective database. Follow-up was according to Dutch guidelines on rectal cancer, with additional rigid rectoscopy and endorectal ultrasound examinations every 3 months for the first 2 years, and every 6 months thereafter. Annual MRI of the lesser pelvis was added during the last 2 years of the study. Patients with local recurrence during follow-up were selected for individual analysis of outcome. RESULTS: Of a total of 88 patients who underwent transanal endoscopic microsurgery for pT1 rectal cancer, 18 patients (20.5%) had a local recurrence. Median time to local recurrence was 10 (range, 4-50) months. Median age at diagnosis of recurrence was 74 (range, 56-84) years. Of the 18 patients, 2 did not undergo further surgery because of concomitant metastatic disease, and 16 underwent salvage surgery, without need for multivisceral resections. No postoperative mortality was observed. In 15 patients (94%), a microscopically negative excision margin was obtained; in 1 patient, the excision margin was microscopically positive. Median follow-up after salvage surgery was 20 (range, 2-112) months. One patient had a local renewal of recurrence, and 7 patients (39%) had distant metastases. At 3 years, overall survival was 31%; cancer-related survival was 58%. CONCLUSIONS: Recurrent disease after transanal endoscopic microsurgery for T1 rectal cancer is a major problem. Although salvage surgery for achieving local control is feasible in most patients, survival is limited, mainly because of distant metastases. Tailoring selection of T1 rectal cancers and exploring possible adjuvant treatment strategies following salvage procedures should be the next steps toward improving survival.
机译:目的:本研究的目的是评估经肛门内镜显微手术治疗T1直肠癌后局部复发的处理和结果。方法:在荷兰转诊中心(艾瑟兰医院)接受经肛门内镜显微手术治疗pT1直肠癌的连续患者在前瞻性数据库中进行注册。根据荷兰关于直肠癌的指南进行随访,头2年每3个月进行一次额外的硬性直肠镜检查和直肠内超声检查,之后每6个月检查一次。在研究的最后两年中,增加了小骨盆的年度MRI。选择随访期间有局部复发的患者进行结局个体分析。结果:在经肛门内镜显微手术治疗pT1直肠癌的88例患者中,有18例(20.5%)局部复发。局部复发的中位时间为10(4-50)个月。诊断复发的中位年龄为74岁(范围56-84)。在18例患者中,有2例由于伴随转移性疾病而没有接受进一步手术,还有16例进行了抢救手术,而无需进行多脏器切除术。没有观察到术后死亡率。在15例患者中(94%),镜下切缘阴性。 1例患者的切除切缘在显微镜下呈阳性。抢救手术后的中位随访时间为20(2-112)个月。 1例患者局部复发,7例患者(39%)发生远处转移。 3年时,总生存率为31%;癌症相关生存率为58%。结论:经肛门内镜显微手术治疗T1直肠癌后的复发性疾病是一个主要问题。尽管对于大多数患者来说,进行抢救手术以实现局部控制是可行的,但生存率有限,这主要是由于远处转移所致。量身定制T1直肠癌的选择,并在挽救程序后探索可能的辅助治疗策略,应是提高生存率的下一步。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号